Vaccine: Fluvirin
Company: Novartis
Approval Date: June 20
Protects Against: Influenza

Fluvirin, Novartis' ($NVS) influenza vaccine approved for the 2012-2013 season June 20, ranked third in a list of top-selling vaccines of 2012. Sales hit an estimated $359 million. Fluvirin is approved for use in people age 4 and older. And this year, Novartis shipped 36 million doses of its vaccine to the United States--a 25% increase over last year. The push comes as a response to high demand, addressing a widespread flu season sweeping the nation. Selling the additional doses should give Novartis' sales a boost.

For more:
Special Report: Top 10 selling flu vaccines of 2012
Nasal delivery: the future of the flu vax


Suggested Articles

AZ's FluMist will be dramatically limited in the U.S. this flu season because of production problems, a spokeswoman said.

As Merck and Pfizer race to market with next-gen vaccines, the companies are fighting in court over a trade secrets lawsuit from Merck.

After working with the government for years to advance a next-gen smallpox vaccine, Bavarian Nordic has finally scored its approval.